AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood test…
Oxford Lane Capital Corp. (the “Company”) (Nasdaq GS: OXLC, OXLCO and OXLCM) today announced that it has priced an underwritten public offering of 3,500,000 shares of its newly designated 6.25% Series 2027 Term Preferred Shares (the “Preferred Stock”) at a public offering price of $25 per share, raising $87.5 million in gross proceeds. The Company has also granted the underwriters a 30-day option to purchase up to 525,000 additional shares of Preferred Stock on the same terms and conditions to cover over-allotments, if any. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American: LTS), and BB&T Capital Markets, a division of BB&T Securities, LLC, are acting as the joint book-running managers for the offering.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has received subscriptions for a private placement in the amount of approximately $6.0 million of units at a price to the public of $2.21425 per unit. Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock. The proceeds of the offering are expected to be used, together with other available funds, for the MicroLine and MicroPine clinical studies, to advance MicroStat’s new drug application, and for working capital and general corporate purposes.
Atomera Incorporated (ATOM), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the semiconductor industry, today announced that it is offering to sell shares of its common stock in an underwritten public offering. Atomera Incorporated intends to use the net proceeds from the offering for working capital and general corporate purposes, which could include capital and/or operating expenditures related to epitaxial deposition tools we may acquire or lease; wafer processing and metrology costs for internal R&D and customer evaluations; and increased engineering personnel supporting Mears Silicon Technology development and customer integration. National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), is acting as the sole book-running manager of the offering.
WhiteHorse Finance, Inc., a business development company (the "Company") (Nasdaq:WHF), today announced that certain of its stockholders (the "Selling Stockholders"), which are funds affiliated with H.I.G. Capital, LLC ("H.I.G. Capital"), plan to make a secondary public offering of shares of common stock of the Company.
Healthcare Trust, Inc. ("HTI" or the "Company") today announced the launch of a proposed underwritten public offering of 1,400,000 shares of its Series A Cumulative Redeemable Perpetual Preferred Stock (the "Series A Preferred Stock"), pursuant to a registration statement on Form S-11 filed with the Securities and Exchange Commission (the "Commission"). The underwriters are expected to be granted a 30-day option to purchase up to an additional 210,000 shares of Series A Preferred Stock. The shares of Series A Preferred Stock have been approved for listing on The Nasdaq Global Market.
To be admitted to the annual meeting at http://www.meetingcenter.io/207776206, stockholders must enter the control number found on their proxy card previously received. Stockholders holding shares through an intermediary, such as a bank or broker, must register in advance with Computershare to attend the annual meeting. Further information regarding this change to the location of the annual meeting, including further instructions for stockholders to be admitted to the annual meeting, can be found in the proxy supplement filed by the Company with the Securities and Exchange Commission on March 23, 2020.
Eyenovia, Inc. (EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, announced that today it closed its previously announced private placement of units which resulted in gross proceeds of $5,984,931 before deducting the placement agent's fees and estimated offering expenses. Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock.
Atomera Incorporated (ATOM), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the semiconductor industry, today announced the closing of its previously announced offering of 2,024,000 shares of common stock at a public offering price of $5.00 per share. The total offering included 264,000 shares sold as a result of the underwriter’s exercise of its overallotment option in full.
ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR‑PB) (“ARMOUR” or the “Company”) today announced the pricing of its underwritten registered public offering of 3 million shares of its new 7.00% Series C Cumulative Redeemable Preferred Stock (the “Series C Preferred Stock”) at a public offering price of $25.00 per share, raising gross proceeds of $75 million before deducting underwriting discounts and other estimated offering expenses. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares on the same terms and conditions solely to cover overallotments, if any. The shares of Series C Preferred Stock are expected to begin trading on the New York Stock Exchange under the symbol “ARR PC” within 30 days of the closing date of this offering, if approved.
Atomera Incorporated (ATOM), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the semiconductor industry, today announced the pricing of an underwritten public offering of 1,760,000 shares of its common stock at a price to the public of $5.00 per share, for gross proceeds of $8.8 million. The Company has also granted to the underwriters a 45-day option to purchase, at the same price per share as the underwriters paid for the initial shares, an additional 264,000 shares to cover over-allotments in connection with the offering, which if exercised in full would increase the gross proceeds to $10,120,000. Atomera Incorporated intends to use the net proceeds from the offering for working capital and general corporate purposes, which could include capital and/or operating expenditures related to epitaxial deposition tools the Company may acquire or lease; wafer processing and metrology costs for internal R&D and customer evaluations; and increased engineering personnel supporting MST development and customer integration.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and ot…
Healthcare Trust, Inc. ("HTI" or the "Company") today announced the pricing of an underwritten public offering of 1,400,000 shares of its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the "Series A Preferred Stock") at a public offering price of $25.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 210,000 shares of Series A Preferred Stock. The shares of Series A Preferred Stock have been approved for listing and are expected to begin trading on The Nasdaq Global Market on December 11, 2019 under the symbol "HTIA." The Series A Preferred Stock will have a $25.00 liquidation preference per share.
WhiteHorse Finance, Inc., a business development company (the "Company") (Nasdaq: WHF), today announced that certain of its stockholders (the "Selling Stockholders"), which are funds affiliated with H.I.G. Capital, LLC ("H.I.G. Capital"), have priced an underwritten, public offering of 2,250,000 shares of common stock of the Company at a public offering price of $13.83 per share pursuant to the Company's shelf registration statement, which was filed with, and has been declared effective by, the Securities and Exchange Commission (the "Commission").
NEW YORK, May 15, 2020 -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, trading.
Oxford Lane Capital Corp. (the “Company”) (NasdaqGS: OXLC, OXLCO and OXLCM) today announced that it plans to offer shares of its newly designated Series 2027 Term Preferred Shares (the “Preferred Stock”) in an underwritten public offering. The public offering price and other terms of the Preferred Stock are to be determined by negotiations between the Company and the underwriters. The Company also plans to grant the underwriters a 30-day option to purchase additional shares of Preferred Stock on the same terms and conditions to cover over-allotments, if any.
Healthcare Trust, Inc. ("HTI" or the "Company") today announced that the underwriters have purchased an additional 210,000 shares of the Company's 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock with a liquidation preference of $25.00 (the "Series A Preferred Stock"), pursuant to the full exercise of the underwriters' option to purchase additional shares in the offering that initially closed on December 11, 2019. The Series A Preferred Stock is listed on The Nasdaq Global Market under the symbol "HTIA."
As a result of this acquisition, National now has 717 registered representatives, and manages in excess of $15 billion of Assets Under Management. Winslow, Evans & Crocker, Inc. (Winslow), is a Boston-based, full-service investment firm established in 1991.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its pre…
NEW YORK, Feb. 14, 2020 -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, tax and.
NEW YORK, Dec. 31, 2019 -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, trading.
CAIS, the leading financial technology platform connecting financial advisors with alternative investments, today announced a new strategic partnership with National Holdings Corporation (NASDAQ: NHLD). National Holdings Corporation, or National, is a leading full-service independent brokerage, investment banking, trading, and asset management firm with over 1000 financial professionals and $16 billion in client assets under management.